San Diego, CA, (USA), Paris (France), – 4 March 2019 – WeHealth by Servier, Servier Group’s e-health department, and, CureMatch, a leader in digital health precision medicine today announced a partnership to jointly bring the CureMatch platform to oncologists, clinics and hospitals around the world.
Today, oncologists face the daunting task of understanding thousands of genomic abnormalities and hundreds of drugs in order to select treatment options for their cancer patients. Powerful new technologies like next generation sequencing have uncovered enormous heterogeneity amongst cancer patients, which tremendously complicates the decision-making process. “Each cancer is like a snowflake—complex and unique,” says Dr. Razelle Kurzrock, one of the world’s leading precision medicine oncologists and CureMatch Founder. “Their genetic profile is unique, their tumors are unique, and their treatment should account for these differences.”
“The vision of WeHealth is to offer a precision medicine approach where the patient is at the center of an individualized diagnosis and treatment. Our collaboration with CureMatch opens a large spectrum of potential benefits for the patients and for oncologists through a better disease management,” says Dr. David Guez, Director General of WeHealth by Servier.
The WeHealth by Servier/CureMatch partnership will bring the best of both worlds together in the fight against cancer. “As a small, innovative company at the leading edge of precision medicine, we know we have something special to offer, but we don’t have the scale or infrastructure of a large company”, says Bob Manning, CEO of CureMatch. “Our partnership with WeHealth will provide corporate size and strength to reach oncologists around the world so much faster than we ever could on our own. The power of the partnership goes beyond the power of WeHealth as it encompasses Servier’s sales and marketing expertise, and provides co-development efforts around additional software development and clinical trial programs.”
About WeHealth by Servier
WeHealth by Servier, launched in November 2016 and aiming to improve the daily life of patients and health professionals’ alike using digital, is the e-Health business unit of the Servier Group. WeHealth by Servier proposes innovative digital and connected solutions as well as services by making the most
of collected data, to ensure better individual monitoring of the patient and to better prevent and predict the evolution of the disease mainly in cardiovascular, neurology, diabetes and oncology fields. In an open innovative approach, WeHealth by Servier identifies the most promising start-ups in e-health, in France and internationally, to co-develop solutions. In this way, WeHealth by Servier contributes to the creation of an ecosystem of partners to facilitate and accelerate the development, industrialization and distribution of innovations and to make them accessible to the greatest number. For further information:
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.2 billion euros in 2018, Servier employs 22 000 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development. More information:
Sonia Marques :– Tel. +33 (0)1 55 72 40 21 / + 33 (0) 7 84 28 76 13
Jean-Clément Vergeau :– Tel. +33 (0)1 55 72 46 16 / + 33 (0) 6 79 56 75 96
Karine Bousseau :– Tel. +33 (0)1 55 72 60 37 / + 33 (0) 6 49 92 16 05
CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch’s Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options.
Bob Manning, CEO